Chemical Information | |
Antiviral agent ID | DrugRepV_3763 | |
Antiviral agent name | MLS000554255 | |
IUPAC Name | 2-[3-[2-hydroxyethyl(dimethyl)azaniumyl]propanoylamino]-2-methylpropane-1-sulfonate | |
SMILES (canonical) | CC(C)(CS(=O)(=O)[O-])NC(=O)CC[N+](C)(C)CCO | |
Molecular Formula | C11H24N2O5S | |
Molecular Weight (g/mol) | 296.382 | |
InChl | InChI=1S/C11H24N2O5S/c1-11(2,9-19(16,17)18)12-10(15)5-6-13(3,4)7-8-14/h14H,5-9H2,1-4H3,(H-,12,15,16,17,18) | |
Synonyms | SMR000146572 | 2-[3-[2-hydroxyethyl(dimethyl)azaniumyl]propanoylamino]-2-methylpropane-1-sulfonate | AC1M0E2N | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Ebola virus (EBOV) NA Mayinga | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | HeLa
| |
Secondary Indication (Viral titer) | 0.075 to 0.15 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Duration of drug delivery) | 24 hours
| |
Secondary Indication (Drug concentration) | 6.8 ± 0.75 μM
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
Secondary Indication (Cytotoxicity) | >50 μM | |
Reference | Anantpadma M, Kouznetsova J, Wang H, Huang R, Kolokoltsov A, Guha R, Lindstrom AR, Shtanko O, Simeonov A, Maloney DJ, Maury W, LaCount DJ, Jadhav A, Davey RA..Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors..Antimicrob Agents Chemother. 2016 Jul 22;60(8):4471-81. doi: 10.1128/AAC.00543-16. Print 2016 Aug. P PMID:27161622
| |
Comment | Each compound blocked infection of primary human macrophages, indicating their potential to be developed as new antifiloviral therapies.
| |